SMITH JASON DREW (General Counsel) sold 17.1% of their position (3.80K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $68.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/5/2023ACC: 0001437749-23-025204
Officer· General Counsel
Since Aug 2020
-3.80K
Net shares
Net seller
$68.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
8.33K acquired · 12.13K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+8.33K
Price / share
—
Trade value
—
% of position
60.1%
8/31/2023
13.87K→22.21K
Ordinary Shares
Direct
Shares
−3.80K
Price / share
$18.01
Trade value
$68.44K
% of position
17.1%
8/31/2023
22.21K→18.41K
Total
Net shares
+4.53K
Net value
-$68.44K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 8/31/2023 | M · Option Exercise | +8.33K | — | — | 60.1% | 13.87K | 22.21K |
| Ordinary Shares Direct | 8/31/2023 | S · Sale | −3.80K | $18.01 | $68.44K | 17.1% | 22.21K | 18.41K |
| Total | +4.53K | -$68.44K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Ordinary Shares
8.33K shares
Shares
−8.33K
Strike price
Held after
0.00
Exercisable
—
8/31/2023
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Ordinary Shares8.33K shares | 8/31/2023 | M · Option Exercise | −8.33K | — | 0.00 |